Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 15;12(4):105-124.
eCollection 2022.

Current trends in diagnosis and management of follicular lymphoma

Gopila Gupta  1 , Vikas Garg  2 , Saumyaranjan Mallick  3 , Ajay Gogia  2
Affiliations
Review

Current trends in diagnosis and management of follicular lymphoma

Gopila Gupta et al. Am J Blood Res. .

Abstract

Follicular lymphoma (FL) originates from germinal center B cells, is the most prevalent form of indolent non-Hodgkin's lymphoma. Upfront management is based on stage, grade, and disease burden. Radiotherapy may be curative in limited disease while chemoimmunotherapy is preferred in advanced disease. Maintenance therapy is routinely administered but its role is debatable. Relapses are common and interval from initial therapy to relapse is most important prognostic factor for relapsed FL. Management of relapsed patients is based on the initial management, the interval from prior therapies, and the toxicity of available therapies. Multiple agents are available for patients after two or more lines of therapy, but sequencing remains poorly defined.

Keywords: CART; EZH2; FL; Follicular lymphoma; NHL; PI3K; chemoimmunotherapy; non-Hodgkin’s lymphoma.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
A. Treatment algorithm for newly diagnosed follicular lymphoma. B. Treatment algorithm for relapsed/refractory follicular lymphoma.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. International Agency for Research on Cancer. WHO Classification of Tumours, Revised 4th Edition, Volume 2.
    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76. - PMC - PubMed
    1. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575–84. - PMC - PubMed
    1. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99:4265–75. - PubMed
    1. Sandhu DS, Sharma A, Kumar L. Non-Hodgkin’s lymphoma in Northern India: an analysis of clinical features of 241 cases. Indian J Med Paediatr Oncol. 2018;39:42.

LinkOut - more resources